Fernando Holguin
Concepts (626)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 128 | 2025 | 1768 | 13.970 |
Why?
| | Obesity | 36 | 2025 | 3082 | 3.390 |
Why?
| | Anti-Asthmatic Agents | 15 | 2025 | 252 | 3.250 |
Why?
| | Air Pollutants | 19 | 2025 | 438 | 2.530 |
Why?
| | Vehicle Emissions | 11 | 2017 | 62 | 2.140 |
Why?
| | Nitric Oxide | 17 | 2025 | 897 | 1.870 |
Why?
| | Citrulline | 3 | 2023 | 46 | 1.840 |
Why?
| | Lung | 26 | 2025 | 4109 | 1.500 |
Why?
| | Air Pollution | 12 | 2024 | 327 | 1.320 |
Why?
| | Adrenal Cortex Hormones | 20 | 2025 | 479 | 1.310 |
Why?
| | Environmental Exposure | 15 | 2025 | 590 | 1.290 |
Why?
| | Minority Groups | 3 | 2021 | 282 | 1.270 |
Why?
| | Biological Products | 2 | 2025 | 252 | 1.260 |
Why?
| | Arginine | 5 | 2023 | 262 | 1.260 |
Why?
| | Metabolic Syndrome | 4 | 2019 | 354 | 1.180 |
Why?
| | Lung Diseases | 5 | 2021 | 787 | 1.140 |
Why?
| | Humans | 163 | 2025 | 144957 | 1.070 |
Why?
| | September 11 Terrorist Attacks | 2 | 2021 | 31 | 1.040 |
Why?
| | Bronchial Hyperreactivity | 4 | 2025 | 96 | 1.030 |
Why?
| | Patient Selection | 2 | 2021 | 719 | 1.010 |
Why?
| | Inflammation | 15 | 2025 | 2880 | 0.990 |
Why?
| | Particulate Matter | 12 | 2025 | 347 | 0.980 |
Why?
| | Severity of Illness Index | 23 | 2025 | 2925 | 0.960 |
Why?
| | Dietary Supplements | 5 | 2019 | 576 | 0.960 |
Why?
| | Forced Expiratory Volume | 16 | 2021 | 449 | 0.920 |
Why?
| | Respiratory Sounds | 3 | 2021 | 105 | 0.920 |
Why?
| | Adult | 75 | 2025 | 40506 | 0.890 |
Why?
| | Hospitalization | 8 | 2020 | 2434 | 0.890 |
Why?
| | Oxidative Stress | 9 | 2024 | 1339 | 0.890 |
Why?
| | Bronchodilator Agents | 9 | 2023 | 183 | 0.850 |
Why?
| | Plant Stems | 1 | 2024 | 8 | 0.840 |
Why?
| | Tocopherols | 1 | 2024 | 30 | 0.830 |
Why?
| | Pulmonary Medicine | 3 | 2021 | 79 | 0.820 |
Why?
| | Glucocorticoids | 5 | 2024 | 535 | 0.820 |
Why?
| | Asteraceae | 1 | 2024 | 20 | 0.820 |
Why?
| | Respiratory Function Tests | 12 | 2025 | 547 | 0.810 |
Why?
| | Mucus | 4 | 2025 | 73 | 0.780 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 93 | 0.780 |
Why?
| | Nitrogen Dioxide | 5 | 2025 | 47 | 0.760 |
Why?
| | Plant Leaves | 1 | 2024 | 137 | 0.750 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 17 | 0.720 |
Why?
| | Fatty Acids, Omega-3 | 4 | 2015 | 142 | 0.710 |
Why?
| | Microalgae | 2 | 2018 | 10 | 0.700 |
Why?
| | Phenotype | 16 | 2025 | 3164 | 0.700 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 10 | 0.700 |
Why?
| | Middle Aged | 57 | 2025 | 35928 | 0.690 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 6 | 2022 | 923 | 0.690 |
Why?
| | Gonadal Steroid Hormones | 2 | 2020 | 144 | 0.690 |
Why?
| | Male | 89 | 2025 | 72406 | 0.680 |
Why?
| | Thiazolidinediones | 2 | 2015 | 139 | 0.680 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 300 | 0.660 |
Why?
| | Female | 88 | 2026 | 78376 | 0.660 |
Why?
| | Transients and Migrants | 2 | 2018 | 27 | 0.640 |
Why?
| | Fluticasone | 5 | 2021 | 53 | 0.640 |
Why?
| | Respiratory Mucosa | 7 | 2025 | 322 | 0.630 |
Why?
| | Heart Rate | 3 | 2013 | 855 | 0.620 |
Why?
| | Hydroxyurea | 1 | 2019 | 34 | 0.620 |
Why?
| | Administration, Inhalation | 15 | 2024 | 575 | 0.620 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2019 | 34 | 0.610 |
Why?
| | Respiratory Tract Diseases | 3 | 2017 | 175 | 0.610 |
Why?
| | Risk Factors | 25 | 2025 | 10792 | 0.610 |
Why?
| | Social Class | 2 | 2021 | 268 | 0.600 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2019 | 8 | 0.590 |
Why?
| | Immunoglobulin E | 7 | 2025 | 315 | 0.590 |
Why?
| | Leptin | 3 | 2011 | 245 | 0.590 |
Why?
| | Carotenoids | 1 | 2019 | 48 | 0.580 |
Why?
| | Stramenopiles | 1 | 2018 | 1 | 0.580 |
Why?
| | Body Mass Index | 14 | 2025 | 2438 | 0.580 |
Why?
| | Adiponectin | 3 | 2011 | 244 | 0.580 |
Why?
| | Biosynthetic Pathways | 1 | 2018 | 25 | 0.570 |
Why?
| | Pulmonary Eosinophilia | 1 | 2018 | 26 | 0.560 |
Why?
| | Age of Onset | 5 | 2018 | 551 | 0.560 |
Why?
| | Young Adult | 27 | 2021 | 14126 | 0.550 |
Why?
| | Bronchoalveolar Lavage Fluid | 10 | 2020 | 636 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1721 | 0.520 |
Why?
| | Biomedical Research | 2 | 2021 | 710 | 0.520 |
Why?
| | Pyridones | 1 | 2019 | 199 | 0.510 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 120 | 0.510 |
Why?
| | Acclimatization | 1 | 2018 | 172 | 0.510 |
Why?
| | Thinness | 3 | 2021 | 99 | 0.500 |
Why?
| | Nitrosative Stress | 1 | 2016 | 4 | 0.500 |
Why?
| | Fluorocarbons | 1 | 2018 | 143 | 0.490 |
Why?
| | United States | 26 | 2025 | 15988 | 0.490 |
Why?
| | Biomarkers | 15 | 2025 | 4275 | 0.480 |
Why?
| | Triglycerides | 1 | 2018 | 521 | 0.480 |
Why?
| | Salmeterol Xinafoate | 3 | 2021 | 20 | 0.480 |
Why?
| | Respiratory Tract Infections | 4 | 2016 | 398 | 0.470 |
Why?
| | Critical Care | 2 | 2021 | 697 | 0.470 |
Why?
| | Adolescent | 36 | 2025 | 22453 | 0.470 |
Why?
| | Dyslipidemias | 1 | 2017 | 182 | 0.460 |
Why?
| | Aedes | 3 | 2026 | 65 | 0.460 |
Why?
| | Soybean Oil | 2 | 2005 | 15 | 0.450 |
Why?
| | Fish Oils | 2 | 2005 | 26 | 0.450 |
Why?
| | Ozone | 4 | 2025 | 132 | 0.450 |
Why?
| | Environmental Monitoring | 6 | 2017 | 378 | 0.440 |
Why?
| | Oxidation-Reduction | 4 | 2018 | 1087 | 0.440 |
Why?
| | Fatty Acids, Omega-6 | 2 | 2015 | 48 | 0.430 |
Why?
| | Epithelial Cells | 8 | 2025 | 1126 | 0.430 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 370 | 0.430 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3415 | 0.420 |
Why?
| | Inflammation Mediators | 3 | 2014 | 509 | 0.420 |
Why?
| | Exhalation | 2 | 2020 | 29 | 0.410 |
Why?
| | Insect Repellents | 2 | 2024 | 7 | 0.410 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 685 | 0.410 |
Why?
| | Child | 36 | 2025 | 22657 | 0.400 |
Why?
| | Carbon Monoxide | 1 | 2013 | 82 | 0.390 |
Why?
| | Eczema | 1 | 2014 | 66 | 0.390 |
Why?
| | Eosinophils | 6 | 2025 | 316 | 0.390 |
Why?
| | Ornithine | 2 | 2023 | 28 | 0.380 |
Why?
| | Morbidity | 3 | 2023 | 323 | 0.380 |
Why?
| | Inhalation Exposure | 1 | 2013 | 115 | 0.380 |
Why?
| | Health Status | 2 | 2024 | 836 | 0.380 |
Why?
| | Aged | 23 | 2024 | 25947 | 0.370 |
Why?
| | Hospital Mortality | 3 | 2020 | 1031 | 0.370 |
Why?
| | Rhinitis | 1 | 2014 | 171 | 0.350 |
Why?
| | Lung Diseases, Obstructive | 1 | 2012 | 43 | 0.350 |
Why?
| | Air Pollutants, Occupational | 1 | 2012 | 42 | 0.350 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 297 | 0.350 |
Why?
| | Immunologic Factors | 1 | 2014 | 255 | 0.340 |
Why?
| | Dust | 1 | 2012 | 102 | 0.340 |
Why?
| | Firefighters | 1 | 2012 | 47 | 0.340 |
Why?
| | Prevalence | 7 | 2020 | 2836 | 0.330 |
Why?
| | Bronchoconstriction | 2 | 2010 | 29 | 0.330 |
Why?
| | Double-Blind Method | 11 | 2019 | 2029 | 0.330 |
Why?
| | Comorbidity | 10 | 2023 | 1660 | 0.330 |
Why?
| | Exercise Test | 2 | 2025 | 634 | 0.330 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2171 | 0.320 |
Why?
| | Eosinophilia | 3 | 2020 | 221 | 0.320 |
Why?
| | Atherosclerosis | 1 | 2014 | 409 | 0.310 |
Why?
| | Sputum | 6 | 2019 | 308 | 0.310 |
Why?
| | Pediatric Obesity | 1 | 2017 | 638 | 0.310 |
Why?
| | Hypersensitivity | 3 | 2022 | 252 | 0.310 |
Why?
| | Airway Resistance | 1 | 2010 | 38 | 0.310 |
Why?
| | Quality of Life | 8 | 2023 | 3192 | 0.310 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 72 | 0.300 |
Why?
| | Air Pollution, Indoor | 3 | 2024 | 181 | 0.300 |
Why?
| | Alendronate | 2 | 2019 | 14 | 0.300 |
Why?
| | Spirometry | 4 | 2023 | 231 | 0.300 |
Why?
| | Pneumocystis carinii | 1 | 2009 | 12 | 0.290 |
Why?
| | Heart Ventricles | 1 | 2014 | 760 | 0.290 |
Why?
| | Overweight | 3 | 2024 | 609 | 0.290 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2009 | 34 | 0.290 |
Why?
| | Intensive Care Units | 2 | 2020 | 916 | 0.290 |
Why?
| | Hydrogen Peroxide | 3 | 2022 | 336 | 0.280 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 33 | 0.280 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 1158 | 0.280 |
Why?
| | Health Services | 1 | 2009 | 115 | 0.280 |
Why?
| | Child, Preschool | 17 | 2025 | 11799 | 0.280 |
Why?
| | Precision Medicine | 3 | 2021 | 458 | 0.270 |
Why?
| | Vasculitis | 1 | 2008 | 69 | 0.270 |
Why?
| | Mexico | 7 | 2013 | 233 | 0.270 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 130 | 0.270 |
Why?
| | Occupational Exposure | 1 | 2012 | 354 | 0.270 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 320 | 0.270 |
Why?
| | Mucins | 2 | 2025 | 76 | 0.270 |
Why?
| | Th2 Cells | 3 | 2019 | 171 | 0.260 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1540 | 0.260 |
Why?
| | Isoprostanes | 1 | 2007 | 15 | 0.260 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5872 | 0.260 |
Why?
| | Schools | 6 | 2021 | 453 | 0.260 |
Why?
| | Health Services Accessibility | 3 | 2024 | 1099 | 0.260 |
Why?
| | Albuterol | 5 | 2023 | 73 | 0.260 |
Why?
| | Bronchi | 3 | 2018 | 267 | 0.260 |
Why?
| | Breath Tests | 4 | 2018 | 79 | 0.260 |
Why?
| | Fatty Acids | 2 | 2021 | 452 | 0.250 |
Why?
| | Treatment Outcome | 10 | 2025 | 11695 | 0.250 |
Why?
| | Aged, 80 and over | 7 | 2020 | 8279 | 0.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 988 | 0.250 |
Why?
| | Cytokines | 5 | 2019 | 2065 | 0.250 |
Why?
| | Disease Progression | 9 | 2025 | 2852 | 0.240 |
Why?
| | Patient Admission | 1 | 2008 | 218 | 0.240 |
Why?
| | Refugees | 2 | 2018 | 83 | 0.240 |
Why?
| | Anopheles | 1 | 2026 | 17 | 0.240 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2609 | 0.240 |
Why?
| | Animal Feed | 1 | 2026 | 54 | 0.240 |
Why?
| | Interleukin-13 | 4 | 2020 | 144 | 0.230 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2947 | 0.230 |
Why?
| | Logistic Models | 4 | 2020 | 2119 | 0.230 |
Why?
| | Chlamydomonas reinhardtii | 2 | 2015 | 8 | 0.220 |
Why?
| | Societies, Medical | 5 | 2023 | 887 | 0.220 |
Why?
| | Animals | 18 | 2026 | 38109 | 0.220 |
Why?
| | Fucosyltransferases | 1 | 2025 | 33 | 0.220 |
Why?
| | Picornaviridae Infections | 1 | 2025 | 50 | 0.220 |
Why?
| | Cholecalciferol | 2 | 2016 | 60 | 0.220 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 79 | 0.220 |
Why?
| | Self Report | 2 | 2019 | 873 | 0.210 |
Why?
| | Leukocyte Count | 4 | 2020 | 316 | 0.210 |
Why?
| | Resins, Plant | 1 | 2024 | 5 | 0.210 |
Why?
| | Rubber | 1 | 2024 | 7 | 0.210 |
Why?
| | Upper Extremity | 1 | 2025 | 112 | 0.210 |
Why?
| | Sex Factors | 4 | 2018 | 2114 | 0.210 |
Why?
| | Prospective Studies | 9 | 2024 | 7997 | 0.200 |
Why?
| | Nitrogen | 2 | 2015 | 170 | 0.200 |
Why?
| | Mexican Americans | 1 | 2004 | 114 | 0.200 |
Why?
| | Lipid Metabolism | 2 | 2018 | 528 | 0.200 |
Why?
| | Microbiota | 3 | 2022 | 781 | 0.200 |
Why?
| | Oils, Volatile | 1 | 2023 | 6 | 0.190 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 93 | 0.190 |
Why?
| | Insect Bites and Stings | 1 | 2023 | 13 | 0.190 |
Why?
| | Arabidopsis | 1 | 2024 | 95 | 0.190 |
Why?
| | Ixodes | 1 | 2023 | 12 | 0.190 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 186 | 0.190 |
Why?
| | Respiration, Artificial | 3 | 2020 | 708 | 0.190 |
Why?
| | Vital Capacity | 4 | 2021 | 290 | 0.190 |
Why?
| | Diet | 3 | 2026 | 1275 | 0.190 |
Why?
| | Respiratory System | 3 | 2020 | 149 | 0.190 |
Why?
| | Proof of Concept Study | 2 | 2019 | 85 | 0.190 |
Why?
| | Housing | 1 | 2024 | 144 | 0.190 |
Why?
| | Reflex | 1 | 2023 | 69 | 0.190 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2019 | 162 | 0.190 |
Why?
| | Vagus Nerve | 1 | 2023 | 91 | 0.180 |
Why?
| | Nutrition Surveys | 3 | 2018 | 282 | 0.180 |
Why?
| | Smoking | 3 | 2020 | 1472 | 0.180 |
Why?
| | Incidence | 5 | 2020 | 2883 | 0.180 |
Why?
| | Quercetin | 1 | 2022 | 18 | 0.180 |
Why?
| | Pilot Projects | 2 | 2019 | 1890 | 0.180 |
Why?
| | Hypersensitivity, Immediate | 2 | 2016 | 40 | 0.180 |
Why?
| | Antioxidants | 4 | 2016 | 549 | 0.180 |
Why?
| | Nitro Compounds | 1 | 2021 | 8 | 0.180 |
Why?
| | Oleic Acids | 1 | 2021 | 12 | 0.180 |
Why?
| | Geography | 2 | 2021 | 203 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 151 | 0.170 |
Why?
| | Omalizumab | 1 | 2021 | 43 | 0.170 |
Why?
| | Waiting Lists | 1 | 2023 | 263 | 0.170 |
Why?
| | Life Style | 2 | 2023 | 479 | 0.170 |
Why?
| | Residence Characteristics | 1 | 2004 | 378 | 0.170 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 326 | 0.170 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 62 | 0.170 |
Why?
| | Arginase | 1 | 2021 | 27 | 0.170 |
Why?
| | Public Policy | 1 | 2021 | 79 | 0.170 |
Why?
| | Automobiles | 3 | 2011 | 18 | 0.170 |
Why?
| | Signal Transduction | 5 | 2020 | 5233 | 0.170 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2018 | 98 | 0.160 |
Why?
| | Patient Advocacy | 1 | 2021 | 74 | 0.160 |
Why?
| | Public Health | 3 | 2018 | 566 | 0.160 |
Why?
| | Disulfides | 1 | 2021 | 96 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2021 | 84 | 0.160 |
Why?
| | Health Policy | 2 | 2021 | 401 | 0.160 |
Why?
| | Geographic Mapping | 1 | 2020 | 29 | 0.160 |
Why?
| | Socioeconomic Factors | 4 | 2018 | 1327 | 0.160 |
Why?
| | Mucin 5AC | 3 | 2025 | 70 | 0.160 |
Why?
| | Geographic Information Systems | 1 | 2020 | 46 | 0.160 |
Why?
| | Self-Management | 1 | 2023 | 201 | 0.160 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 164 | 0.160 |
Why?
| | Chemotaxis | 1 | 2020 | 122 | 0.160 |
Why?
| | Case-Control Studies | 6 | 2020 | 3608 | 0.160 |
Why?
| | Soot | 3 | 2015 | 25 | 0.160 |
Why?
| | Lung Transplantation | 1 | 2023 | 338 | 0.160 |
Why?
| | Dyspnea | 1 | 2022 | 251 | 0.150 |
Why?
| | Frailty | 1 | 2023 | 198 | 0.150 |
Why?
| | Puberty | 2 | 2018 | 140 | 0.150 |
Why?
| | Muscarinic Antagonists | 1 | 2019 | 30 | 0.150 |
Why?
| | Neutrophils | 3 | 2020 | 1134 | 0.150 |
Why?
| | Poverty | 1 | 2024 | 530 | 0.150 |
Why?
| | Age Factors | 5 | 2018 | 3335 | 0.150 |
Why?
| | Gene Expression | 4 | 2018 | 1490 | 0.150 |
Why?
| | Th1 Cells | 2 | 2017 | 139 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 62 | 0.150 |
Why?
| | Uncertainty | 1 | 2020 | 145 | 0.150 |
Why?
| | Nitric Oxide Synthase | 2 | 2019 | 235 | 0.150 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 26 | 0.150 |
Why?
| | Mometasone Furoate | 1 | 2019 | 3 | 0.150 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 5 | 0.150 |
Why?
| | Trust | 1 | 2021 | 153 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 346 | 0.150 |
Why?
| | Mucin-4 | 1 | 2019 | 3 | 0.150 |
Why?
| | Sialyltransferases | 1 | 2019 | 13 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 35 | 0.150 |
Why?
| | 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2018 | 7 | 0.150 |
Why?
| | Saline Waters | 1 | 2018 | 1 | 0.150 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.140 |
Why?
| | Immunity | 2 | 2022 | 139 | 0.140 |
Why?
| | Gastroesophageal Reflux | 1 | 2021 | 236 | 0.140 |
Why?
| | Dioxanes | 1 | 2018 | 10 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2642 | 0.140 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 212 | 0.140 |
Why?
| | Immunoglobulin Fragments | 1 | 2018 | 11 | 0.140 |
Why?
| | Cities | 4 | 2013 | 143 | 0.140 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1495 | 0.140 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 193 | 0.140 |
Why?
| | Moraxella | 1 | 2018 | 5 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 96 | 0.140 |
Why?
| | Porosity | 1 | 2018 | 96 | 0.140 |
Why?
| | Airway Remodeling | 2 | 2016 | 64 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2025 | 601 | 0.140 |
Why?
| | DNA Methylation | 1 | 2023 | 683 | 0.140 |
Why?
| | Adsorption | 1 | 2018 | 157 | 0.140 |
Why?
| | Water | 2 | 2018 | 469 | 0.140 |
Why?
| | Weight Loss | 2 | 2023 | 837 | 0.140 |
Why?
| | Interferon-gamma | 2 | 2025 | 784 | 0.130 |
Why?
| | Corynebacterium | 1 | 2018 | 49 | 0.130 |
Why?
| | Metabolome | 2 | 2018 | 384 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.130 |
Why?
| | Silicon Dioxide | 1 | 2018 | 121 | 0.130 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2021 | 24 | 0.130 |
Why?
| | Emergency Service, Hospital | 2 | 2025 | 2313 | 0.130 |
Why?
| | Cold Temperature | 1 | 2018 | 209 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1325 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2023 | 17101 | 0.130 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 6053 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 660 | 0.130 |
Why?
| | Volatile Organic Compounds | 1 | 2017 | 60 | 0.120 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 9 | 0.120 |
Why?
| | Leukotriene Antagonists | 1 | 2016 | 23 | 0.120 |
Why?
| | Mice | 9 | 2025 | 18365 | 0.120 |
Why?
| | Voice Quality | 1 | 2016 | 23 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 280 | 0.120 |
Why?
| | Water Purification | 1 | 2018 | 157 | 0.120 |
Why?
| | Functional Food | 1 | 2016 | 4 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2020 | 2832 | 0.120 |
Why?
| | Food Quality | 1 | 2016 | 11 | 0.120 |
Why?
| | Chemokines, CC | 2 | 2014 | 32 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 153 | 0.120 |
Why?
| | Pigments, Biological | 1 | 2016 | 17 | 0.120 |
Why?
| | Vitamins | 2 | 2015 | 178 | 0.120 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5997 | 0.120 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2015 | 10 | 0.120 |
Why?
| | Crops, Agricultural | 1 | 2016 | 31 | 0.120 |
Why?
| | Quinolones | 1 | 2018 | 201 | 0.120 |
Why?
| | Bronchoconstrictor Agents | 1 | 2015 | 14 | 0.120 |
Why?
| | Zea mays | 1 | 2016 | 43 | 0.120 |
Why?
| | Income | 1 | 2017 | 202 | 0.120 |
Why?
| | Ibuprofen | 1 | 2016 | 84 | 0.120 |
Why?
| | Vermont | 1 | 2015 | 13 | 0.120 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 97 | 0.120 |
Why?
| | Aminophenols | 1 | 2018 | 201 | 0.120 |
Why?
| | Anthocyanins | 1 | 2016 | 31 | 0.120 |
Why?
| | Methacholine Chloride | 1 | 2015 | 50 | 0.120 |
Why?
| | Bronchial Provocation Tests | 1 | 2015 | 47 | 0.120 |
Why?
| | Antigens, CD | 1 | 2019 | 555 | 0.120 |
Why?
| | Preventive Medicine | 1 | 2016 | 39 | 0.120 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 6 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 647 | 0.110 |
Why?
| | Seeds | 1 | 2016 | 74 | 0.110 |
Why?
| | Health Surveys | 2 | 2009 | 518 | 0.110 |
Why?
| | Bariatric Surgery | 1 | 2019 | 242 | 0.110 |
Why?
| | Blood Platelets | 1 | 2019 | 400 | 0.110 |
Why?
| | Homocysteine | 1 | 2015 | 151 | 0.110 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2015 | 3 | 0.110 |
Why?
| | Transportation | 1 | 2015 | 54 | 0.110 |
Why?
| | Azithromycin | 1 | 2015 | 104 | 0.110 |
Why?
| | Healthcare Disparities | 2 | 2023 | 728 | 0.110 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 978 | 0.110 |
Why?
| | Fibrinogen | 1 | 2015 | 177 | 0.110 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 148 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2738 | 0.110 |
Why?
| | Pennsylvania | 4 | 2016 | 138 | 0.100 |
Why?
| | Pregnenediones | 1 | 2014 | 14 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 917 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2015 | 255 | 0.100 |
Why?
| | Photosynthesis | 1 | 2014 | 98 | 0.100 |
Why?
| | Interleukin-6 | 2 | 2016 | 780 | 0.100 |
Why?
| | Acetaminophen | 1 | 2016 | 264 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2017 | 321 | 0.100 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2016 | 194 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 417 | 0.100 |
Why?
| | Cells, Cultured | 5 | 2020 | 4155 | 0.100 |
Why?
| | Cohort Studies | 8 | 2020 | 5965 | 0.100 |
Why?
| | Receptors, Prostaglandin | 1 | 2013 | 21 | 0.100 |
Why?
| | Linear Models | 4 | 2018 | 854 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 22 | 0.100 |
Why?
| | Nutritional Status | 1 | 2015 | 354 | 0.100 |
Why?
| | Odds Ratio | 1 | 2015 | 1077 | 0.100 |
Why?
| | Lipids | 2 | 2015 | 710 | 0.100 |
Why?
| | Metallurgy | 1 | 2012 | 9 | 0.090 |
Why?
| | Chemokine CCL24 | 1 | 2012 | 11 | 0.090 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 302 | 0.090 |
Why?
| | Dinoprost | 2 | 2009 | 49 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2015 | 320 | 0.090 |
Why?
| | Texas | 4 | 2017 | 278 | 0.090 |
Why?
| | Macrophages, Alveolar | 3 | 2015 | 368 | 0.090 |
Why?
| | Time Factors | 2 | 2015 | 7183 | 0.090 |
Why?
| | Brazil | 2 | 2023 | 180 | 0.090 |
Why?
| | Particle Size | 3 | 2011 | 411 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4569 | 0.090 |
Why?
| | Mucin-5B | 2 | 2025 | 234 | 0.090 |
Why?
| | Diet, High-Fat | 2 | 2025 | 261 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1253 | 0.090 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 206 | 0.090 |
Why?
| | Weight Gain | 1 | 2015 | 559 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1786 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 2032 | 0.080 |
Why?
| | Leukotriene E4 | 1 | 2011 | 24 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2019 | 2050 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1137 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2385 | 0.080 |
Why?
| | Glutathione Transferase | 2 | 2009 | 100 | 0.080 |
Why?
| | Functional Residual Capacity | 1 | 2010 | 7 | 0.080 |
Why?
| | Mental Health | 1 | 2017 | 792 | 0.080 |
Why?
| | Inhalation | 1 | 2010 | 29 | 0.080 |
Why?
| | Alabama | 1 | 2009 | 33 | 0.080 |
Why?
| | Nitrites | 1 | 2009 | 89 | 0.080 |
Why?
| | Illinois | 1 | 2009 | 47 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 57 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2025 | 3125 | 0.070 |
Why?
| | Nitrates | 1 | 2009 | 100 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1241 | 0.070 |
Why?
| | Tyrosine | 1 | 2009 | 222 | 0.070 |
Why?
| | Plasmapheresis | 1 | 2008 | 23 | 0.070 |
Why?
| | Gases | 1 | 2009 | 53 | 0.070 |
Why?
| | Chlorine | 1 | 2009 | 64 | 0.070 |
Why?
| | Mice, Obese | 1 | 2007 | 66 | 0.070 |
Why?
| | California | 1 | 2009 | 475 | 0.070 |
Why?
| | Depression | 2 | 2016 | 1559 | 0.060 |
Why?
| | Pneumonia | 2 | 2020 | 631 | 0.060 |
Why?
| | Mutation | 1 | 2018 | 4099 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2009 | 539 | 0.060 |
Why?
| | Employer Health Costs | 1 | 2006 | 4 | 0.060 |
Why?
| | Medication Adherence | 2 | 2023 | 539 | 0.060 |
Why?
| | Glutathione | 1 | 2009 | 375 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2009 | 250 | 0.060 |
Why?
| | PPAR gamma | 1 | 2007 | 177 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3869 | 0.060 |
Why?
| | Phagocytosis | 1 | 2008 | 299 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2021 | 282 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2019 | 402 | 0.060 |
Why?
| | Blood | 1 | 2026 | 109 | 0.060 |
Why?
| | Palmitic Acid | 1 | 2025 | 42 | 0.060 |
Why?
| | Bronchoscopy | 3 | 2012 | 227 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 386 | 0.060 |
Why?
| | Acute Lung Injury | 1 | 2009 | 303 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 96 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2009 | 901 | 0.060 |
Why?
| | Rhinovirus | 1 | 2025 | 57 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2008 | 405 | 0.060 |
Why?
| | Health Expenditures | 1 | 2006 | 194 | 0.060 |
Why?
| | Biopsy | 1 | 2008 | 1077 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 559 | 0.050 |
Why?
| | Child Day Care Centers | 1 | 2005 | 44 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1915 | 0.050 |
Why?
| | Homeostasis | 1 | 2009 | 640 | 0.050 |
Why?
| | Fats | 1 | 2024 | 17 | 0.050 |
Why?
| | Glycosylation | 1 | 2025 | 172 | 0.050 |
Why?
| | Infant | 5 | 2018 | 10039 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2008 | 462 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2024 | 39 | 0.050 |
Why?
| | Cost of Illness | 1 | 2006 | 321 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 2 | 2015 | 89 | 0.050 |
Why?
| | Survival Rate | 1 | 2009 | 2092 | 0.050 |
Why?
| | Up-Regulation | 2 | 2020 | 852 | 0.050 |
Why?
| | Hormones | 1 | 2024 | 134 | 0.050 |
Why?
| | Chemokine CCL26 | 2 | 2014 | 10 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 285 | 0.050 |
Why?
| | Nursing Homes | 1 | 2005 | 172 | 0.050 |
Why?
| | Cattle | 1 | 2026 | 1000 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 340 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 4293 | 0.050 |
Why?
| | Epigenomics | 1 | 2023 | 114 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 25 | 0.050 |
Why?
| | Recurrence | 2 | 2016 | 1135 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2584 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2005 | 233 | 0.050 |
Why?
| | Hand Strength | 1 | 2023 | 144 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2025 | 724 | 0.050 |
Why?
| | Americas | 1 | 2022 | 26 | 0.050 |
Why?
| | Feces | 1 | 2025 | 513 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 427 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 529 | 0.040 |
Why?
| | Biology | 1 | 2023 | 91 | 0.040 |
Why?
| | Latin America | 1 | 2022 | 94 | 0.040 |
Why?
| | Glycocholic Acid | 1 | 2021 | 2 | 0.040 |
Why?
| | Antigens, Dermatophagoides | 1 | 2021 | 10 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 77 | 0.040 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 17 | 0.040 |
Why?
| | Respiratory Hypersensitivity | 1 | 2021 | 65 | 0.040 |
Why?
| | Expectorants | 1 | 2021 | 23 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 434 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 1095 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 621 | 0.040 |
Why?
| | Dermatitis, Atopic | 1 | 2024 | 321 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 3154 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 194 | 0.040 |
Why?
| | International Cooperation | 2 | 2011 | 198 | 0.040 |
Why?
| | Canada | 1 | 2022 | 428 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 1046 | 0.040 |
Why?
| | New York City | 1 | 2020 | 89 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 35 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2026 | 685 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 230 | 0.040 |
Why?
| | Altitude | 2 | 2016 | 473 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 672 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 174 | 0.040 |
Why?
| | Research | 1 | 2023 | 431 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 283 | 0.040 |
Why?
| | Trichloroethanes | 1 | 2018 | 1 | 0.040 |
Why?
| | Trichloroethylene | 1 | 2018 | 8 | 0.040 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2019 | 59 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 355 | 0.040 |
Why?
| | Patient Discharge | 1 | 2005 | 983 | 0.040 |
Why?
| | Stroke | 1 | 2008 | 1258 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1048 | 0.040 |
Why?
| | Indians, North American | 1 | 2024 | 647 | 0.030 |
Why?
| | Groundwater | 1 | 2018 | 41 | 0.030 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 25 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2020 | 268 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 392 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2365 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.030 |
Why?
| | Mouth Mucosa | 1 | 2018 | 88 | 0.030 |
Why?
| | Growth | 1 | 2018 | 49 | 0.030 |
Why?
| | Epithelium | 1 | 2019 | 314 | 0.030 |
Why?
| | Nose | 1 | 2018 | 68 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 250 | 0.030 |
Why?
| | Cyclohexenes | 1 | 2017 | 5 | 0.030 |
Why?
| | Chlorobenzenes | 1 | 2017 | 19 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1389 | 0.030 |
Why?
| | Toluene | 1 | 2017 | 12 | 0.030 |
Why?
| | Pentanes | 1 | 2017 | 11 | 0.030 |
Why?
| | Xylenes | 1 | 2017 | 8 | 0.030 |
Why?
| | Benzene | 1 | 2017 | 18 | 0.030 |
Why?
| | Terpenes | 1 | 2017 | 25 | 0.030 |
Why?
| | Oils | 1 | 2017 | 22 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 384 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2016 | 36 | 0.030 |
Why?
| | Biomass | 1 | 2017 | 116 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1407 | 0.030 |
Why?
| | Crop Production | 1 | 2016 | 1 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 466 | 0.030 |
Why?
| | Communication | 1 | 2023 | 967 | 0.030 |
Why?
| | Succinates | 1 | 2016 | 24 | 0.030 |
Why?
| | Plant Breeding | 1 | 2016 | 20 | 0.030 |
Why?
| | Southwestern United States | 1 | 2016 | 95 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 351 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 386 | 0.030 |
Why?
| | Glucosides | 1 | 2016 | 55 | 0.030 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2015 | 5 | 0.030 |
Why?
| | Receptors, Interleukin-17 | 1 | 2015 | 6 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 189 | 0.030 |
Why?
| | Algal Proteins | 1 | 2015 | 6 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1423 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 198 | 0.030 |
Why?
| | Hospital Costs | 1 | 2016 | 124 | 0.030 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 234 | 0.030 |
Why?
| | Industry | 1 | 2015 | 43 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1153 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1629 | 0.030 |
Why?
| | Photosystem I Protein Complex | 1 | 2014 | 2 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 134 | 0.030 |
Why?
| | Chlorophyll | 1 | 2014 | 15 | 0.030 |
Why?
| | Proton-Motive Force | 1 | 2014 | 8 | 0.030 |
Why?
| | Thylakoids | 1 | 2014 | 6 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2017 | 348 | 0.030 |
Why?
| | Hydroxylation | 1 | 2015 | 49 | 0.030 |
Why?
| | Carbon Cycle | 1 | 2014 | 14 | 0.030 |
Why?
| | Starch | 1 | 2014 | 22 | 0.030 |
Why?
| | Fever | 1 | 2016 | 312 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2016 | 310 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 574 | 0.030 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2014 | 57 | 0.030 |
Why?
| | Chemokine CXCL9 | 1 | 2014 | 38 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 118 | 0.030 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 24 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 119 | 0.030 |
Why?
| | Exons | 1 | 2015 | 358 | 0.030 |
Why?
| | Sepsis | 1 | 2020 | 641 | 0.030 |
Why?
| | Fluorescence | 1 | 2014 | 161 | 0.030 |
Why?
| | Docosahexaenoic Acids | 1 | 2015 | 83 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 233 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1416 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2014 | 144 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 199 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 112 | 0.030 |
Why?
| | Critical Illness | 1 | 2020 | 892 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 392 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Temperature | 1 | 2017 | 679 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 783 | 0.020 |
Why?
| | Colorado | 1 | 2024 | 4564 | 0.020 |
Why?
| | Risk | 1 | 2016 | 911 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2882 | 0.020 |
Why?
| | Acute Disease | 1 | 2016 | 1031 | 0.020 |
Why?
| | Lipocalins | 1 | 2013 | 35 | 0.020 |
Why?
| | Treatment Failure | 1 | 2014 | 365 | 0.020 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2013 | 66 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 476 | 0.020 |
Why?
| | Steel | 1 | 2012 | 6 | 0.020 |
Why?
| | Meteorological Concepts | 1 | 2012 | 6 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2012 | 25 | 0.020 |
Why?
| | Genome | 1 | 2015 | 306 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 983 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1888 | 0.020 |
Why?
| | Spatio-Temporal Analysis | 1 | 2012 | 39 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 627 | 0.020 |
Why?
| | Heart Failure | 1 | 2005 | 2323 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2201 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 341 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 848 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 863 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2011 | 69 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3676 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2118 | 0.020 |
Why?
| | Pain | 1 | 2016 | 782 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 886 | 0.020 |
Why?
| | Proteome | 1 | 2015 | 518 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 889 | 0.020 |
Why?
| | Seasons | 1 | 2012 | 556 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 995 | 0.020 |
Why?
| | Chemical Hazard Release | 1 | 2009 | 1 | 0.020 |
Why?
| | Railroads | 1 | 2009 | 6 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 218 | 0.020 |
Why?
| | Glutathione Reductase | 1 | 2009 | 25 | 0.020 |
Why?
| | Malondialdehyde | 1 | 2009 | 30 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2009 | 16 | 0.020 |
Why?
| | Glutathione Peroxidase | 1 | 2009 | 39 | 0.020 |
Why?
| | South Carolina | 1 | 2009 | 48 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1110 | 0.020 |
Why?
| | Voice Disorders | 1 | 2009 | 22 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 936 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2008 | 15 | 0.020 |
Why?
| | Cough | 1 | 2009 | 124 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 582 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5417 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3550 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2013 | 846 | 0.020 |
Why?
| | Office Visits | 1 | 2006 | 90 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 310 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2006 | 285 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2006 | 603 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1839 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2430 | 0.010 |
Why?
|
|
Holguin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|